HCPCS Code J1559: Injection, Immune Globulin (Hizentra), 100 mg

Learn about HCPCS Code J1559 for Hizentra immune globulin injection with billing requirements, documentation guidelines, relevant codes, and more.

Use Code

## **What is an Immune Globulin (Hizentra) Injection?** HCPCS code J1559 refers to injection, immune globulin (Hizentra), 100 mg. Hizentra is a strictly subcutaneous immune globulin used to treat conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiency disorders, and severe combined immunodeficiency (SCID). It is not administered intravenously. It is typically administered subcutaneously using a syringe-type cartridge and an external infusion pump. This delivery method allows patients to maintain near-normal immunoglobulin levels, helping manage symptoms for a few weeks between infusions. Hizentra is billed under Medicare Part B as a parenteral drug provided through durable medical equipment (DME). Medicare Part B specifically requires the use of the JB modifier to indicate subcutaneous administration via an infusion pump or syringe-type device. Claims should also include documentation of professional services, pump setup, and necessary supplies. This treatment is especially important for patients with predominant antibody defects, low T or B cell numbers, or adenosine deaminase deficiency, where maintaining increased immunoglobulin levels is critical for health management.

## **HCPCS code J1559 documentation requirements** Accurate documentation is critical when billing HCPCS code J1559 for injection immune globulin Hizentra, 100 mg. Providers must include a clear statement of the patient’s diagnosis (e.g., primary immunodeficiency disorders [ICD-10 D80-D84], chronic inflammatory demyelinating polyneuropathy [ICD-10 G61.81]) and evidence of medical necessity. Records should specify the dosage administered (in 100 mg units), method of administration (e.g., subcutaneous injection via infusion pump or syringe-type cartridge), date of treatment, and lot number for regulatory traceability (Coding Health, 2024). Physician orders must align with the billed dosage, and documentation of professional services, pump setup, or required supplies should be maintained. Use of the JB modifier to confirm subcutaneous delivery is required, and records must note any dose adjustments or adverse reactions to support claims and facilitate smooth reimbursement.

## **J1559 billing requirements** - **Route-specific modifier**: When billing Medicare Part B for Hizentra administered subcutaneously via infusion pump or syringe-type device, use the JB modifier to specify the subcutaneous route. This ensures correct billing for the parenteral drug - **Drug wastage reporting**: Medicare requires reporting of unused portions of single-use vials or syringes under the JW modifier for discarded amounts, or the JZ modifier if none were discarded. Since Hizentra is commonly supplied as prefilled syringes or cartridges, wastage reporting with these modifiers applies only when applicable. Documentation of wastage amounts should be maintained in clinical records. - **Units billed**: Each 100 mg of Hizentra equates to one billing unit. Claims must accurately report the total dosage administered in units of 100 mg. - **Place of service and reimbursement rates**: As a Drugs Administered Other than Oral Method service requiring moderate medical decision-making, J1559 falls under Medicare Part B’s scope. Typical Medicare reimbursement averages around $14.79 per 100 mg unit; however, rates can vary by region and payer. Providers should consult local fee schedules and payer-specific policies for precise reimbursement amounts. - **Include relevant DME components if applicable**: When Hizentra is provided using a pump, the drug itself is billed separately under J1559, while the infusion pump and supplies are billed under durable medical equipment guidelines according to DME MAC policies. These components may require separate claims and potentially prior authorization distinct from the drug.

## **Other relevant codes** - J1561 – Injection, immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g., liquid), 500 mg - J1569 – Injection, immune globulin, (Gammagard liquid), non-lyophilized (e.g., liquid), 500 mg

Coding Health. (2024, December 3). HCPCS Code J1559: How to bill & recover revenue. https://coding.health/hcpcs-code-j1559/

Frequently asked questions

The code description for J1559 is “Injection, immune globulin (Hizentra), 100 mg.” It applies when billing for Hizentra, a subcutaneous immune globulin therapy.

Hizentra is delivered through a subcutaneous infusion site, typically in the abdomen, thigh, upper arm, or hip. Multiple sites may be used at once depending on the prescribed dose and patient tolerance.

In most cases, J1559 does not require a modifier code. However, some payers may request modifiers if multiple infusions or an additional pump setup is used. Always check payer-specific guidelines.

Hizentra is commonly prescribed for patients with predominantly antibody defects (immune disorders where antibody production is impaired). These lead to recurrent infections and require ongoing immunoglobulin replacement to maintain immune defense.